CDC Panel Endorses Expanded Use of Pfizer and Merck Pneumococcal Vaccines for Adults 50-64

The CDC's Advisory Committee on Immunization Practices (ACIP) has endorsed the expansion of pneumococcal vaccines to include adults aged 50-64, as well as adults aged 19-49 with certain risk factors, pending final approval from the CDC director and the Department of Health and Human Services[1][2]. This broadening of recommendations covers Merck’s Capvaxive and Pfizer’s Prevnar 20, which previously targeted primarily those over 65 and certain younger adults with risk factors. This move is expected to advance health equity, improve access, and boost vaccination rates for these age groups. Both pharmaceutical companies have welcomed the decision, anticipating an expanded market and enhanced public health outcomes[1][2].